78 citations
,
October 2003 in “Cochrane library” Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
2 citations
,
May 2023 in “Al Mustansiriyah Journal of Pharmaceutical Sciences” Pterostilbene significantly reduces prostate enlargement and has strong antioxidant effects.
7 citations
,
August 1985 in “British journal of dermatology/British journal of dermatology, Supplement” Medroxyprogesterone acetate injections are more effective than topical ointment in treating excessive hair growth in women.
January 2004 in “Drug Development and Industrial Pharmacy” GI197111X is best dissolved in Capmul MCM for trials.
18 citations
,
July 2008 in “Current Oncology Reports” EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
253 citations
,
April 2009 in “Journal of Biological Chemistry” p2y5, now called LPA6, is a receptor important for human hair growth.
December 2024 in “Frontiers in Pharmacology” Araliadiol may promote hair growth like minoxidil without being toxic.
October 2019 in “Asian College of Neuropsychopharmacology”
October 2023 in “IBRO neuroscience reports” Rat hair follicle stem cells have functional oxytocin receptors, useful for studying neuropsychiatric disorders.
15 citations
,
April 2001 in “Journal of Dermatological Science” KF19418 promotes hair growth similarly to minoxidil but is not better in live mice.
57 citations
,
May 2014 in “Molecular Phylogenetics and Evolution” The research found how GPCR Class A Rhodopsin receptors are related and suggested possible substances they interact with.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
12 citations
,
February 2017 in “Journal of neuroscience research” Removing certain brain receptors in mice worsens seizure severity and response to treatment during hormone withdrawal.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
1 citations
,
May 2001 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.
April 2021 in “Journal of Investigative Dermatology” People with atopic dermatitis have more CD4+ T cells that respond to a certain bacterial lipid, which may play a role in the skin condition's inflammation.
1 citations
,
December 2016 in “Journal of Pakistan Association of Dermatology” Medroxyprogesterone acetate iontophoresis safely and effectively reduces facial hair growth in women.
10 citations
,
June 2005 in “The journal of investigative dermatology/Journal of investigative dermatology” FP-1 is a key protein in rat hair growth, active only during the growth phase.
10 citations
,
January 2000 in “PubMed” Both finasteride and GnRH agonist treatments reduced hair growth in women with idiopathic hirsutism, but GnRH agonist was more effective.
1 citations
,
January 2007 in “Side effects of drugs annual” Dermatological treatments can have significant side effects, including allergic reactions, sexual dysfunction, and increased cancer risk.
2 citations
,
October 2001 in “Analytical Sciences” A new compound that could treat various androgen-related conditions was created and analyzed.
20 citations
,
May 2007 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Etanercept effectively treated a severe skin condition when other treatments failed.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
34 citations
,
July 2006 in “The Journal of Comparative Neurology” Increasing neurotrophin 4 in skin boosts nerve endings but not sensory neuron count.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
4 citations
,
June 2024 in “British Journal of Dermatology” EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.